[go: up one dir, main page]

NO20070930L - Stabiliserende formuleringer - Google Patents

Stabiliserende formuleringer

Info

Publication number
NO20070930L
NO20070930L NO20070930A NO20070930A NO20070930L NO 20070930 L NO20070930 L NO 20070930L NO 20070930 A NO20070930 A NO 20070930A NO 20070930 A NO20070930 A NO 20070930A NO 20070930 L NO20070930 L NO 20070930L
Authority
NO
Norway
Prior art keywords
protein
storing
methods
relatively low
stabilizing formulations
Prior art date
Application number
NO20070930A
Other languages
English (en)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070930L publication Critical patent/NO20070930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SAMMENDRAG Det er beskrevet formuleringer s om er egnet for lagring av proteiner, slik som antistoffer, over et relativt bredt spekter av proteinkonsentrasjoner, pH og buffertyper. Også beskrevet er metoder for lagring av et protein og metoder for 'a identifisere en egnet formulering for lagring av et bestemt protein. Generelt omfatter en formulering lav mengde til ingen surfaktant, ingen til relativt lave saltkonsentrasjoner og krever en relativt lav bufferkonsentrasjon.
NO20070930A 2004-08-13 2007-02-19 Stabiliserende formuleringer NO20070930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13
PCT/US2005/028861 WO2006020935A2 (en) 2004-08-13 2005-08-12 Stabilizing formulations

Publications (1)

Publication Number Publication Date
NO20070930L true NO20070930L (no) 2007-05-14

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070930A NO20070930L (no) 2004-08-13 2007-02-19 Stabiliserende formuleringer

Country Status (18)

Country Link
US (1) US8871201B2 (no)
EP (1) EP1784219B1 (no)
JP (1) JP4948407B2 (no)
KR (1) KR20070092197A (no)
CN (1) CN101022831A (no)
AR (1) AR051009A1 (no)
AU (1) AU2005272603A1 (no)
BR (1) BRPI0514340A (no)
CA (1) CA2575870A1 (no)
CR (1) CR8904A (no)
EC (1) ECSP077246A (no)
ES (1) ES2637854T3 (no)
IL (1) IL181265A0 (no)
MX (1) MX2007001599A (no)
NO (1) NO20070930L (no)
RU (1) RU2007109062A (no)
TW (1) TW200621282A (no)
WO (1) WO2006020935A2 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
MX2008013535A (es) * 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
AU2008334099B2 (en) * 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
PT2473527T (pt) 2009-09-03 2017-02-27 Ablynx Nv Formulações estáveis de polipéptidos e seus usos
BR112013033671B1 (pt) 2011-07-01 2022-10-18 Biogen Ma Inc Composições de polipeptídeo de fusão fc livre de arginina e uso
US9623087B2 (en) 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
PL2830658T3 (pl) * 2012-03-26 2019-02-28 Sanofi Stabilne formulacje środków wiążących lgG4
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CA2929525A1 (en) 2013-11-04 2015-05-07 Pfizer Inc. Anti-efna4 antibody-drug conjugates
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3194977B1 (en) * 2014-07-21 2019-10-02 Unchained Labs Determination of protein aggregation from the concentration dependence of delta g
KR20240095372A (ko) 2015-04-29 2024-06-25 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
KR102534506B1 (ko) 2016-08-18 2023-05-30 리제너론 파마슈티칼스 인코포레이티드 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
RS65694B1 (sr) 2017-01-05 2024-07-31 Radius Pharmaceuticals Inc Polimorfni oblici rad1901-2hcl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
TW202245823A (zh) * 2021-01-14 2022-12-01 南韓商韓兀生物製藥股份有限公司 無穩定劑或實質上無穩定劑之含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）的穩定眼用組成物
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176517D1 (en) 1980-04-24 1987-12-17 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ATE444358T1 (de) 1997-06-04 2009-10-15 Oxford Biomedica Ltd Tumor gezielter vektor
IL133220A0 (en) 1997-06-13 2001-03-19 Genentech Inc Stabilized antibody formulation
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
EP1254666A4 (en) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
EP1507556B1 (en) 2002-05-02 2016-07-27 Wyeth Holdings LLC Calicheamicin derivative-carrier conjugates
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN1867587A (zh) 2003-08-14 2006-11-22 惠氏公司 抗Lewis Y抗独特型抗体及其用途
MX2007002826A (es) 2004-09-10 2007-04-27 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados de anticuerpos anti-5t4/caliqueamicina.

Also Published As

Publication number Publication date
EP1784219A4 (en) 2010-02-17
TW200621282A (en) 2006-07-01
ES2637854T3 (es) 2017-10-17
JP4948407B2 (ja) 2012-06-06
JP2008515775A (ja) 2008-05-15
EP1784219A2 (en) 2007-05-16
KR20070092197A (ko) 2007-09-12
CR8904A (es) 2007-08-28
AR051009A1 (es) 2006-12-13
EP1784219B1 (en) 2017-05-17
MX2007001599A (es) 2007-04-10
AU2005272603A1 (en) 2006-02-23
RU2007109062A (ru) 2008-09-20
CA2575870A1 (en) 2006-02-23
BRPI0514340A (pt) 2008-06-10
WO2006020935A2 (en) 2006-02-23
US20060115472A1 (en) 2006-06-01
US8871201B2 (en) 2014-10-28
CN101022831A (zh) 2007-08-22
IL181265A0 (en) 2007-07-04
WO2006020935A3 (en) 2007-03-08
ECSP077246A (es) 2007-05-30

Similar Documents

Publication Publication Date Title
NO20070930L (no) Stabiliserende formuleringer
Simpson Stabilization of proteins for storage
Lin et al. Immunolocalization of H+-ATPase in the gill epithelia of rainbow trout
JP2008515775A5 (no)
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
ECSP088962A (es) Nuevos herbicidas
Bailey et al. Protective effects of osmolytes in cryopreserving adherent neuroblastoma (Neuro-2a) cells
CH688194A5 (fr) Composition stabilisée de troponine pour immunoessais et procédé de stabilisation de troponine pour immunoessais.
PL407889A1 (pl) Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę trangeniczne
EP1371643A3 (en) Method of preparing organic peroxyacids
Ceyhun et al. In vitro and in vivo effects of some pesticides on carbonic anhydrase enzyme from rainbow trout (Oncorhynchus mykiss) gills
Hou et al. Analysis of glutathione in biological samples by HPLC involving pre-column derivatization with o-phthalaldehyde
Di Martino Bap: a new type of functional amyloid
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
Cleal et al. Modification of fetal plasma amino acid composition by placental amino acid exchangers in vitro
JP2014501526A5 (no)
AR017251A1 (es) Método para reducir el dano causado a los cultivos mediante un herbicida de tetrazolinona y composiciones herbicidas.
JP2021061802A (ja) Ｌ−グルタミンの測定方法、及びそのためのキット
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
Furla et al. Diffusional permeability of dissolved inorganic carbon through the isolated oral epithelial layers of the sea anemone, Anemonia viridis
Haindrich et al. Nutrient availability regulates proline/alanine transporters in Trypanosoma brucei
Durand et al. Increases in tissue free amino acid levels in response to prolonged emersion in marine crabs: an ammonia-detoxifying process efficient in the intertidal Carcinus maenas but not in the subtidal Necora puber
US9879250B2 (en) Protein-stabilizing agent and protein-stabilizing method
Tsikas Extra-platelet low-molecular-mass thiols mediate the inhibitory action of S-nitrosoalbumin on human platelet aggregation via S-transnitrosylation of the platelet surface
ES2321373T3 (es) Procedimiento para la estabilizacion de proteinas en mezclas complejas durante su almacenamiento en disolventes acuosos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application